Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

June 22, 2011 By Bio-Medicine.Org

EVANSTON, Ill., June 22, 2011 /PRNewswire/ — Naurex
Inc., a clinical-stage company developing innovative treatments to
address unmet needs in psychiatry and neurology, today announced
that it has initiated a Phase II clinical trial of its lead
compound GLYX-13.  GLYX-13, a Glycine-site Functional Partial
Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is
initially being developed as a therapy for patients who are not
achieving an adequate response to their current antidepressant
agents.  Screening and enrollment of subjects in the Phase II
study are currently underway.

Naurex’s novel GFPA class of compounds has demonstrated the
potential to achieve the well-documented efficacy of classic
NMDAR-modulating drugs while avoiding their serious side effects.
 Known NMDAR-modulating agents such as ketamine have been
shown to act very rapidly — within hours of a single dose — to
alleviate the symptoms of depression and bipolar disorder in a
number of human clinical trials, but their clinical utility has
been hampered by their potential for abuse and behavioral
impairment, including schizophrenia-like effects at doses near the
therapeutic dose.

The GLYX-13 Phase II trial is a randomized, double-blind,
placebo-controlled study of the efficacy and safety of GLYX-13 in
treatment-resistant depression.  The trial is intended to
enroll 80 subjects with major depressive disorder who have
demonstrated inadequate or partial response to other
antidepressants.  Outcome measures include ratings of signs,
symptoms, and changes in depression scores on standard rating
scales for mood and psychiatric disorders.  Safety is also
being assessed.

“GLYX-13 is the first in a new class of antidepressants designed
to achieve the rapid onset and breakthrough efficacy of classic
NMDAR modulators, but without their prohibitive side effects,” said
Ronald Burch, M.D., Ph.D., chief medical officer at Naurex.
 “T

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech